title: [Modified FLAG regimen in the management of refractory acute myeloid leukemia].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).
  
  
  METHODS
  Sixteen patients with refractory AML were divided into two groups. In modified FLAG regimen group (n=10), the patients received fludarabine (Flu, 50 mg/d, VDx5 d) and Ara-c (200 mg/d, VDx5 or 7 d). The regimen for classic FLAG group (n=6) consisted of Flu (50 mg/d, VDx5d), Ara-C (500 or 1,000 mg/d, VDx5d) and G-CSF (300 microg/d, x5 d, subcutaneously injected 4-6 hours before chemotherapy). Each patient received subcutaneous G-CSF (300 microg/d) when the white blood cell count was lower than 1.0x10(9)/L till the condition was corrected.
  
  
  RESULTS
  The total complete remission(CR) rate of the 16 patients was 50% (8/16). Seven patients in modified group achieved CR (70%) and only one of the classic group did (17%, P<0.05). Episodes of infections were lower in modified group than in the classic group (50% vs 83%).
  
  
  CONCLUSIONS
  Modified FLAG regimen is more likely than classic FLAG regimen to achieve CR and reduce infections in patients with refractory AML.
authors.affiliation: Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. yanglongjiang@hotmail.com
authors.forename: Long-jiang
authors.initials: LJ
authors.lastname: Yang
authors.forename: Fan-yi
authors.initials: FY
authors.lastname: Meng
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Liu
authors.forename: Wei-yang
authors.initials: WY
authors.lastname: Zheng
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Fen
authors.initials: F
authors.lastname: Huang
authors.forename: Dan
authors.initials: D
authors.lastname: Xu
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Qi-fa
authors.initials: QF
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014740:Vidarabine; C024352:fludarabine